News & Updates

Show Multimedia Only

Apixaban recommended for thromboprophylaxis in ovarian cancer patients on chemo

09 Sep 2025 by

Data presented at ESMO Gyn 2025 support apixaban as a prophylactic agent for venous thromboembolism (VTE) in women with epithelial ovarian cancer who are undergoing neoadjuvant chemotherapy consisting of carboplatin and paclitaxel.

Apixaban recommended for thromboprophylaxis in ovarian cancer patients on chemo

09 Sep 2025

Real-world data support HPV vaccine efficacy in off-label age groups

09 Sep 2025 by

A prospective analysis demonstrates the effectiveness of HPV vaccination in reducing progression to biopsy-confirmed precancerous lesions and HPV persistence in a cohort of South Korean women in off-label age groups.

Real-world data support HPV vaccine efficacy in off-label age groups

09 Sep 2025

Antihistamine nasal spray a promising prophylactic treatment against SARS-CoV-2

08 Sep 2025 by

The use of the antihistamine nasal spray azelastine may help prevent SARS-CoV-2 respiratory infections, as shown in a phase II study.

Antihistamine nasal spray a promising prophylactic treatment against SARS-CoV-2

08 Sep 2025

Propafenone reduces risks of proarrhythmia, death in AF patients with HF

08 Sep 2025

The use of propafenone shows no significant relationship with an elevated risk of proarrhythmia and mortality compared with amiodarone in atrial fibrillation (AF) patients with heart failure (HF), suggests a recent study.

Propafenone reduces risks of proarrhythmia, death in AF patients with HF

08 Sep 2025

Alirocumab lowers LDL-C levels in patients with ACS

08 Sep 2025

Long-term treatment with alirocumab with or without lipid-lowering therapy treatment significantly reduced the levels of low-density lipoprotein cholesterol (LDL-C) in patients with acute coronary syndrome (ACS), as shown by the results of a real-world evidence study.

Alirocumab lowers LDL-C levels in patients with ACS

08 Sep 2025

Raludotatug deruxtecan shows efficacy signal in platinum-sensitive ovarian cancer

07 Sep 2025 by

The cadherin 6 (CDH6)-directed antibody–drug conjugate raludotatug deruxtecan elicits response in heavily pretreated patients with platinum-sensitive ovarian cancer while having a manageable safety profile, according to a subgroup analysis of an ongoing first-in-human phase I trial.

Raludotatug deruxtecan shows efficacy signal in platinum-sensitive ovarian cancer

07 Sep 2025

Thumbs up for rucaparib maintenance across prognostic subgroups of HRD-negative ovarian cancer

06 Sep 2025 by

Maintenance with the PARP inhibitor rucaparib after first-line platinum-doublet chemotherapy and cytoreductive surgery appears to reduce the risk of progression in the homologous recombination deficiency (HRD)-negative population of patients with advanced, high-grade ovarian cancer enrolled in the phase III ATHENA-MONO trial, no matter the prognostic factor.

Thumbs up for rucaparib maintenance across prognostic subgroups of HRD-negative ovarian cancer

06 Sep 2025

Chlorthalidone trumps HCTZ for stone prevention; morning dosing preferable

06 Sep 2025 by

Calcium stone formers prefer the long-acting and more effective chlorthalidone for stone prevention, reports a study. The time of administration appears irrelevant, but morning administration may be more effective in addressing higher postdinner calcium excretion.

Chlorthalidone trumps HCTZ for stone prevention; morning dosing preferable

06 Sep 2025

Selinexor maintenance shows consistent benefit in TP53wt endometrial cancer

06 Sep 2025 by

Selinexor maintenance therapy continues to show consistent clinical benefit in patients with TP53 wild-type (TP53wt) advanced or recurrent endometrial cancer, regardless of mismatch repair (MMR) status, according to the ENGOT-EN5/GOG-3055/SIENDO trial presented at ESMO Gyn 2025.

Selinexor maintenance shows consistent benefit in TP53wt endometrial cancer

06 Sep 2025

First-line durvalumab plus tremelimumab safe to use in unresectable HCC

05 Sep 2025 by

The phase IIIb SIERRA study has shown an acceptable safety profile for the single tremelimumab regular interval durvalumab (STRIDE) regimen as first-line treatment for patients with hepatocellular carcinoma (HCC) who have a poor prognosis.

First-line durvalumab plus tremelimumab safe to use in unresectable HCC

05 Sep 2025

News & Updates

Filter by Specialty:

Specialty:

Apixaban recommended for thromboprophylaxis in ovarian cancer patients on chemo

Apixaban recommended for thromboprophylaxis in ovarian cancer patients on chemo

Real-world data support HPV vaccine efficacy in off-label age groups

Real-world data support HPV vaccine efficacy in off-label age groups

Antihistamine nasal spray a promising prophylactic treatment against SARS-CoV-2

Antihistamine nasal spray a promising prophylactic treatment against SARS-CoV-2

Propafenone reduces risks of proarrhythmia, death in AF patients with HF

Propafenone reduces risks of proarrhythmia, death in AF patients with HF

Alirocumab lowers LDL-C levels in patients with ACS

Alirocumab lowers LDL-C levels in patients with ACS

Raludotatug deruxtecan shows efficacy signal in platinum-sensitive ovarian cancer

Raludotatug deruxtecan shows efficacy signal in platinum-sensitive ovarian cancer

Thumbs up for rucaparib maintenance across prognostic subgroups of HRD-negative ovarian cancer

Thumbs up for rucaparib maintenance across prognostic subgroups of HRD-negative ovarian cancer

Chlorthalidone trumps HCTZ for stone prevention; morning dosing preferable

Chlorthalidone trumps HCTZ for stone prevention; morning dosing preferable

Selinexor maintenance shows consistent benefit in TP53wt endometrial cancer

Selinexor maintenance shows consistent benefit in TP53wt endometrial cancer

First-line durvalumab plus tremelimumab safe to use in unresectable HCC

First-line durvalumab plus tremelimumab safe to use in unresectable HCC